DENVER, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, announced today that it held its annual general meeting of shareholders on December 28, 2022 (the “Meeting”) and that all matters submitted to the shareholders of the Company for approval as set out in the Company’s definitive proxy statement dated December 2, 2022 (the “Proxy Statement”), were approved by the requisite majority of votes cast at the Meeting, including:
For further details regarding the matters approved at the Meeting, please see a copy of the Proxy Statement, which is available on the Company’s profile at www.sec.gov.
About Assure Holdings
Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services. The Company delivers a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive procedures that place the nervous system at risk including neurosurgery, spine, cardiovascular, orthopedic and ear, nose and throat surgeries. Assure employs highly trained technologists that provide a direct point of contact in the operating room. Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients’ neural structures throughout the procedure communicating in real-time with the surgeon and technologist. Accredited by The Joint Commission, Assure’s mission is to provide exceptional surgical care and a positive patient experience. For more information, visit the company’s website at www.assureneuromonitoring.com.
Contact
Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-617-2526
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.05 |
Daily Volume: | 0 |
Market Cap: | US$141K |
February 12, 2024 August 15, 2023 August 03, 2023 June 26, 2023 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB